New Zealand markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1,063.60-3.66 (-0.34%)
At close: 04:00PM EDT
1,083.00 +19.40 (+1.82%)
After hours: 07:53PM EDT
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
3,857,800
3,953,600
4,338,400
8,075,300
3,513,200
-
Depreciation & amortisation
435,600
421,000
341,400
286,200
235,900
-
Deferred income taxes
-811,700
-837,800
-746,400
-147,100
75,600
-
Stock-based compensation
876,400
885,000
725,000
601,700
432,000
-
Change in working capital
105,500
-94,100
-243,300
-1,916,500
-1,503,600
-
Accounts receivable
-102,100
-338,800
707,800
-1,927,400
-1,356,100
-
Inventory
-380,700
-271,700
-696,500
-494,300
-529,400
-
Accounts payable
590,100
598,600
-138,400
866,100
118,900
-
Other working capital
3,929,800
3,667,600
3,398,000
6,529,400
2,003,500
-
Other non-cash items
-20,600
-100
563,000
568,700
86,800
-
Net cash provided by operating activities
4,738,900
4,594,000
5,014,900
7,081,300
2,618,100
-
Cash flows from investing activities
Investments in property, plant and equipment
-809,100
-926,400
-1,616,900
-551,900
-614,600
-
Acquisitions, net
-
-54,900
-230,300
0
-
-
Purchases of investments
-15,554,100
-11,646,000
-7,487,900
-7,048,100
-3,241,000
-
Sales/maturities of investments
11,781,600
9,442,200
5,550,500
2,215,300
3,785,000
-
Other investing activities
-
-
-230,300
-
-
-
Net cash used for investing activities
-4,636,500
-3,185,100
-3,784,600
-5,384,700
-70,600
-
Cash flows from financing activities
Debt repayment
-
-
0
0
-1,500,000
0
Common stock issued
1,342,400
1,145,500
1,519,500
1,672,300
2,575,200
-
Common stock repurchased
-2,762,900
-2,935,600
-2,528,500
-2,678,100
-6,527,600
-
Other financing activities
-
-
-
-
-
-188,000
Net cash used provided by (used for) financing activities
-1,420,500
-1,790,100
-1,009,000
-1,005,800
-1,970,500
-
Net change in cash
-1,319,000
-381,600
221,300
690,800
577,000
-
Cash at beginning of period
3,928,800
3,119,400
2,898,100
2,207,300
1,630,300
-
Cash at end of period
2,610,700
2,737,800
3,119,400
2,898,100
2,207,300
-
Free cash flow
Operating cash flow
4,738,900
4,594,000
5,014,900
7,081,300
2,618,100
-
Capital expenditure
-809,100
-926,400
-1,616,900
-551,900
-614,600
-
Free cash flow
3,929,800
3,667,600
3,398,000
6,529,400
2,003,500
-